Thrombocytopenia due to immune destruction
MONDO:0002048A general class of thrombocytopenia due to immune destruction of platelets. It includes idiopathic thrombocytopenic purpura, as well as immune destruction-related thrombocytopenias due to other reasons (e.g., AIDS, transfusion, lupus erythematosus).
Also known as: immune thrombocytopenia, thrombocytopenia due to immune destruction, auto-immune thrombocytopenia, thrombocytopenia due to platelet alloimmunization
82 clinical trials for this condition and its sub-types, 81 tagged with Thrombocytopenia due to immune destruction itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
Can a gut bacteria transplant help when steroids fail for a bleeding disorder?
Disease control OngoingThis phase 2 trial tests whether fecal microbiota transplantation (FMT) — transferring gut bacteria from a healthy donor — can help adults with chronic immune thrombocytopenia (ITP) whose disease has not responded to or has relapsed after steroid treatment. Participants will rece…
Phase 2 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New drug RAY121 tested for Long-Term control of autoimmune diseases
Disease control By invitation onlyThis study is a long-term extension of an earlier trial, testing the safety of a drug called RAY121 in people with six different immune system disorders, including antiphospholipid syndrome and immune thrombocytopenia. Participants have already completed four doses of RAY121 and …
Phase 1 • Sponsor: Chugai Pharmaceutical • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Could a cancer drug fix blood cell problems after transplant?
Disease control OngoingThis phase 2 trial tests whether isatuximab can help people whose blood cell counts stay low after a stem cell transplant for blood cancer. The study enrolls 12 adults whose disease is in remission but who have developed immune-related blood cell deficiencies. Participants receiv…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New pill could help people with low platelet disorder
Disease control OngoingThis phase 3 trial tests an oral drug called rilzabrutinib in 232 adults and adolescents with persistent or chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, raising bleeding risk. Participants receive either rilzabrutinib or a placebo…
Phase 3 • Sponsor: Principia Biopharma, a Sanofi Company • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New combo therapy shows promise for rare bleeding disorder
Disease control OngoingThis study tests whether adding diammonium glycyrrhizinate (a liver-protecting compound) to standard high-dose dexamethasone can improve platelet counts in adults newly diagnosed with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing b…
Phase 2 • Sponsor: Shandong University • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
Study withdrawn: extended access to fostamatinib for transplant patients never launched
Disease control CancelledThis study was designed to give people who had a stem cell transplant and developed low blood cell counts (anemia, low platelets) continued access to the drug fostamatinib. Only those who responded well in a prior study were eligible. The goal was to see if they could maintain st…
Phase 2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New oral drug shows promise for Long-Term control of rare bleeding disorder
Disease control OngoingThis study is for adults with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding and bruising. It tests the long-term safety and benefit of an oral drug called rilzabrutinib. Only 4 participants who already benefited fr…
Phase 3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Promising ITP drug trial pulled before it even started
Disease control CancelledThis study was designed to test the safety and tolerability of a new drug called HMPL-523 (sovleplenib) in adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding problems. The trial was withdrawn before enrolling any pa…
Phase 1 • Sponsor: Hutchmed • Aim: Disease control
Last updated Jun 26, 2026 18:23 UTC
-
Will a new drug form work the same? study tests two versions of SKI-O-703
Knowledge-focused OngoingThis study tests whether two different capsule forms of the experimental drug SKI-O-703 are absorbed similarly in the body. About 48 healthy adults (Korean and Caucasian) will take a single dose of each form on separate days, with blood samples taken to compare drug levels. The r…
Phase 1 • Sponsor: Oscotec Inc. • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC